<DOC>
	<DOCNO>NCT02914639</DOCNO>
	<brief_summary>The primary purpose study evaluate safety exploratory efficacy SF0166 Topical Ophthalmic Solution patient Neovascular ( wet ) Age-related Macular Degeneration ( AMD ) .</brief_summary>
	<brief_title>Safety Exploratory Efficacy Study SF0166 Treatment Neovascular Age-Related Macular Degeneration ( AMD )</brief_title>
	<detailed_description>This prospective , randomize , double-masked , multicenter , Phase I/II clinical study 40 eligible subject Neovascular Age-related Macular Degeneration ( AMD ) randomize 1 2 treatment arm 1:1 ratio follow : SF0166 low dose twice daily ( BID ) SF0166 high dose BID . The study population include male female subject , age 50 old , active subfoveal choroidal neovascularization due Age-related Macular Degeneration ( AMD ) meet follow criterion : ≤12 Macular Photocoagulation Study [ MPS ] disc area , choroidal neovascularization [ CNV ] &gt; 50 % total lesion area ) , retinal subretinal fluid visible optical coherence tomography ( OCT ) , treatment anti-vascular endothelial growth factor ( VEGF ) therapy study eye within 60 day study entry . If subject qualifies eye , SF0166 may administer eye ( study eye non-study eye ) discretion Investigator . Study subject administer randomly assign treatment 28 day . There additional 28-day post-treatment follow-up period . All study subject return examination every 2 week 8 week ( 2 month ) . All outcomes assessment summarize descriptively Days 0 , 14 , 28 , 42 , 56 . No formal hypothesis test .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>1 . Male female , 50 year age old . 2 . Active subfoveal choroidal neovascularization due Agerelated Macular Degeneration ( AMD ) study eye meet follow criterion : Total lesion ≤12 Macular Photocoagulation Study ( MPS ) disc area Choroidal neovascularization ( CNV ) &gt; 50 % lesion area Intraretinal subretinal fluid due choroidal neovascularization ( CNV ) visible optical coherence tomography ( OCT ) No atrophy fibrosis involve center fovea 3 . Bestcorrected Visual Acuity ( BCVA ) 78 25 letter , inclusive , study eye screening/randomization visit use Early Treatment Diabetic Retinopathy Study ( ETDRS ) testing , BCVA decrement primarily attributable neovascular Agerelated Macular Degeneration ( AMD ) . 4 . Treatment naïve ( i.e. , previous antivascular endothelial growth factor [ VEGF ] treatment study eye ) previously treat study eye adequate washout define : 1 . Lucentis ( ranibizumab ) : 30day washout 2 . Avastin ( bevacizumab ) : 30day washout 3 . Eylea ( aflibercept ) : 60day washout 4 . Macugen ( pegaptanib ) : 45day washout 5 . Willing able return study visit . 6 . Able adhere study dose requirement . 7 . Understands sign write informed consent form . 1 . Nonstudy eye best correct visual acuity ( BCVA ) worse 20 letter screening/randomization visit use Early Treatment Diabetic Retinopathy Study ( ETDRS ) test . 2 . Choroidal neovascularization ( CNV ) study eye secondary cause ( e.g. , pathologic myopia , ocular histoplasmosis syndrome , angioid streak , choroidal rupture , posterior uveitis , multifocal choroiditis ) . 3 . Previous macular laser photocoagulation ocular photodynamic therapy study eye . 4 . Media opacities abnormality study eye would preclude visualization retina . 5 . Other retinal pathology study eye would interfere vision . 6 . Retinal pigment epithelial ( RPE ) tear study eye . 7 . Significant epiretinal membrane , posterior hyaloidal traction , and/or vitreomacular traction study eye determine optical coherence tomography ( OCT ) result . 8 . Uncontrolled glaucoma ocular hypertension study eye define Intraocular Pressure ( IOP ) &gt; 25 millimeter mercury ( mmHg ) regardless concomitant treatment IOP lowering medication . 9 . Uncontrolled hypertension define systolic &gt; 180 mmHg &gt; 160 mmHg 2 consecutive measurement ( visit ) diastolic &gt; 100 mmHg optimal medical regimen 10 . Previous par plana vitrectomy study eye . 11 . Any intraocular surgery study eye within 90 day ( 3 month ) prior study enrollment . 12 . Yttrium aluminium garnet ( YAG ) laser treatment study eye within 30 day ( 1 month ) prior study enrollment . 13 . Intravitreal/periocular/topical ocular steroid type study eye within 90 day ( 3 month ) prior study enrollment . 14 . Concomitant use topical ophthalmic medication study eye , include dry eye glaucoma medication , unless stable dose least 90 day ( 3 month ) prior study enrollment expect stay stable dose throughout study participation . Artificial tear allow . 15 . Chronic recurrent uveitis study eye . 16 . Ongoing ocular infection inflammation either eye . 17 . A history cataract surgery complicate vitreous loss study eye . 18 . Congenital eye malformation study eye . 19 . A history penetrate ocular trauma study eye . 20 . Mentally handicap . 21 . Females childbearing potential ( i.e. , postmenopausal least 1 year surgically sterile least 6 week prior Visit 1 Screening/Randomization ) lactating , pregnant determine positive urine pregnancy test ( UPT ) Visit 1 Screening/Randomization . Women childbearing potential must agree use acceptable method birth control throughout study . Acceptable method birth control include tubal ligation , transdermal patch , intrauterine devices/systems , oral/implantable/injectable contraceptive , sexual abstinence , double barrier method , vasectomized partner . 22 . Participation investigational device drug clinical research study within 30 day Visit 1 Screening/Randomization . 23 . Contraindication study medication fluorescein dye . 24 . Other ocular pathology Investigator 's opinion would interfere vision study eye .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>